Faculty

Institution

Unit

Venue

Vinh Q. Nguyen

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Rheumatology

The University of Texas MD Anderson Cancer Center

NoneVinh Q. Nguyen is currently serving as a Rheumatology faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Vinh Q. Nguyen

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

medicine hematology oncology pharmacotherapy hematological malignancies lymphoid neoplasia radiation oncology clinical trials systemic treatment older patients immunology pharmacology cancer immunotherapy immunotherapy therapeutic targets laboratory medicine cellular therapy medicinal research clinical transplantation leukemia jama oncology anti-cancer agents cell therapy cancer treatment first-line therapy frontline treatment brexucabtagene autoleucel window-3 clinical trial mantle cell lymphoma

Notable Scholarly Works

Notable Federal Grants

Collaborators

Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel for Frontline Treatment of High-Risk Mantle Cell Lymphoma: The Window-3 Clinical Trial. Blood (2025)

hematological malignanciesmedicineleukemiahematologyradiation oncologyfrontline treatmentlymphoid neoplasiapharmacotherapybrexucabtagene autoleucelclinical trialsoncologysystemic treatmentwindow-3 clinical trial

Acalabrutinib With Rituximab is Highly Effective First Line Treatment for Older Patients With Mantle Cell Lymphoma. Blood (2024)

hematological malignanciesmedicinemantle cell lymphomahematologyradiation oncologylymphoid neoplasiapharmacotherapytherapeutic targetsoncologysystemic treatmentjama oncologyolder patients

Acalabrutinib With Rituximab as First-Line Therapy for Older Patients With Mantle Cell Lymphoma - a Phase II Clinical Trial. Blood (2023)

Preetesh JainChi Young OKLoretta J. NastoupilJason WestinHolly A HillRanjit NairSwami P. IyerAhmed FetoohHun Ju LeeSairah AhmedRashmi Kanagal-ShamannaFatima Z JelloulLuis Enrique Malpica CastilloYang LiuYijing LiJovanny VargasLei FengMaria BadilloSelvi ThirumurthiGuofan XuAnita DeswalCezar IliescuVinh Quang NguyenGuilin TangKeyur P. PatelFrancisco VegaL. Jeffrey MedeirosMichael L. WangChristopher R. Flowers

hematological malignanciesolder patientsmedicinehematologyanti-cancer agentslaboratory medicinecell therapylymphoid neoplasiacancer immunotherapycancer treatmentimmunotherapyimmunologypharmacologypharmacotherapycellular therapyclinical trialsoncologyfirst-line therapymedicinal researchclinical transplantation

1
10 / page

Vinh Q. Nguyen

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Rheumatology

The University of Texas MD Anderson Cancer Center

NoneVinh Q. Nguyen is currently serving as a Rheumatology faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Vinh Q. Nguyen

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel for Frontline Treatment of High-Risk Mantle Cell Lymphoma: The Window-3 Clinical Trial. Blood (2025)

Acalabrutinib With Rituximab is Highly Effective First Line Treatment for Older Patients With Mantle Cell Lymphoma. Blood (2024)

hematological malignanciesmedicinemantle cell lymphomahematologyradiation oncologylymphoid neoplasiapharmacotherapytherapeutic targetsoncologysystemic treatmentjama oncologyolder patients

Acalabrutinib With Rituximab as First-Line Therapy for Older Patients With Mantle Cell Lymphoma - a Phase II Clinical Trial. Blood (2023)

1
10 / page